<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03328299</url>
  </required_header>
  <id_info>
    <org_study_id>402</org_study_id>
    <nct_id>NCT03328299</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Dynamics of Dexmedetomidine as Adjuvant in TAP Block</brief_title>
  <official_title>Pharmacokinetics and Dynamics of Dexmedetomidine as Adjuvant in TAP Block for Patient Undergoing Lower Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      TAP-block has been shown to be a safe and effective postoperative analgesia method in a
      variety of general. Dexmedetomidine is a selective α2 agonist with 8 times more affinity for
      α2 adrenergic receptors compared to clonidine and possesses all the properties of α2 agonist
      without respiratory depression. Dexmedetomidine has been focus of interest for its broad
      spectrum (sedative, analgesic and anesthetic sparing) properties, making it a useful and safe
      adjunct in many clinical applications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the total dose of IV PCA morphine consumption in the first 24 h postoperative</measure>
    <time_frame>24 hours</time_frame>
    <description>postoperative morphine consumption</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>assessment of systemic dexmedetomidine level after local administration</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>assessment of systemic dexmedetomidine level after local administration in TAP block after 15 minutes after giving the block, 30 min, 45 min, 1hrs, 2hrs, 4hrs and 6 hrs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients were given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine + dexmedetomidine 1 μg•kg-1 diluted in 20 ml saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivacaine group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients will given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>20 ml of 0.5 % bupivacaine plus dexmedetomidine 1 μg•kg-1</description>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <other_name>active group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine</intervention_name>
    <description>20 ml of 0.5 % bupivacaine</description>
    <arm_group_label>bupivacaine group</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  60 ASA I-II

          -  patients (age 18-60 years

          -  weight 50-89 kg

        Exclusion Criteria:

          -  a known allergy to the study drugs

          -  significant cardiac

          -  respiratory, renal or hepatic diseases

          -  bleeding diathesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>South Egypt Cancer instIitute</name>
      <address>
        <city>Assuit</city>
        <zip>171516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>fatma ad el sherif, lecturer</last_name>
      <phone>088233018</phone>
      <email>fatma_anesthesia@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>December 24, 2017</last_update_submitted>
  <last_update_submitted_qc>December 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Fatma Adel El sherif</investigator_full_name>
    <investigator_title>lecturer of anesthesia , ICU and pain management</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

